에 대한 최신 뉴스 Aptose Biosciences (OTC:APTOF) 주식

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

APTOSE BIOSCIENCES INC by Aptose Biosciences. Inc.

Aptose Biosciences Inc

Press Releases

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Earnings

Aptose Reports First Quarter 2025 Results

News

Health Care

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

APTO

APTOF

TSX:APS

Aptose Biosciences

Comments

Aptose Biosciences

뉴스

에 대한 최신 뉴스 Aptose Biosciences (OTC:APTOF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌